Effect of Efavirenz on the Pharmacokinetics of SHR6390 in Healthy Volunteers

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2024 Jul 25

PMID 39050802

Authors

Jin Wang

Chaoying Hu

Lan Zhang

Affiliations

Soon will be listed here.

Abstract

Purpose: SHR6390 is an oral, potent and selective small-molecule CDK4/6 inhibitor for the treatment of human breast, ovarian and colon cancer. Previous studies have shown that SHR6390 in combination with rifampicin, a potent inducer of CYP3A4, significantly reduces exposure levels. Therefore, we further investigated the effect of efavirenz, a moderate CYP3A4 inducer, on a single oral dose of SHR6390 in healthy volunteers.

Patients And Methods: Twenty healthy subjects were enrolled in this single-center, open, single-dose, self-controlled DDI study. On Day 1, subjects received a single oral dose of 150mg SHR6390; on Day 8-26, subjects received 600 mg efavirenz orally at night, with a single dose of 150 mg SHR6390 on Day 22. Blood samples for pharmacokinetic analyses were collected.

Results: The geometric mean ratios of the maximum concentration(C) and the area under the concentration curve from zero to infinity (AUC) between combination therapy and SHR6390 monotherapy (combination therapy/SHR6390 monotherapy) and their 90% confidence intervals were 0.562 (0.482, 0.654) and 0.328 (0.278, 0.386), respectively. This indicates that the Cmax and AUC0 inf of SHR6390 decreased by approximately 43.8% and 67.2%, respectively. Oral administration of 150 mg SHR6390 alone or together with efavirenz was safe and tolerable in healthy subjects.

Conclusion: It is suggested that under the action of the moderate CPY3A4 inducer efavirenz, the exposure AUC of SHR6390 exhibits a moderate level of induction. It is recommended to avoid concomitant administration of moderate inducers of CYP3A4 during treatment with SHR6390.

Trial Registration: http://www.chinadrugtrials.org.cn/index.html, CTR20211571/ https://classic.clinicaltrials.gov, NCT04973020.

References

Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z . Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021; 27(11):1904-1909. DOI: 10.1038/s41591-021-01562-9. View

Zhang P, Xu B, Gui L, Wang W, Xiu M, Zhang X . A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. Biomark Res. 2021; 9(1):24. PMC: 8042970. DOI: 10.1186/s40364-021-00271-2. View

Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, Boyer S . Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med. 2019; 381(9):816-826. DOI: 10.1056/NEJMoa1904340. View

Wood D, Endicott J . Structural insights into the functional diversity of the CDK-cyclin family. Open Biol. 2018; 8(9). PMC: 6170502. DOI: 10.1098/rsob.180112. View

. [Chinese guidelines for diagnosis and treatment of HIV/AIDS (2021 edition)]. Zhonghua Nei Ke Za Zhi. 2021; 60(12):1106-1128. DOI: 10.3760/cma.j.cn112138-20211006-00676. View

. Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial. Lancet. 2014; 383(9927):1474-1482. DOI: 10.1016/S0140-6736(13)62187-X. View

Wang J, Li Q, Yuan J, Wang J, Chen Z, Liu Z . CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest. J Transl Med. 2017; 15(1):127. PMC: 5457542. DOI: 10.1186/s12967-017-1231-7. View

Spring L, Wander S, Andre F, Moy B, Turner N, Bardia A . Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020; 395(10226):817-827. DOI: 10.1016/S0140-6736(20)30165-3. View

Liu C, Shi J, Lin B, Zhou M, Shan D, Nie J . SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model. Curr Gene Ther. 2022; 24(5):453-464. DOI: 10.2174/1566523222666220825110147. View

10.

Carey D, Puls R, Amin J, Losso M, Phanupak P, Foulkes S . Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study. Lancet Infect Dis. 2015; 15(7):793-802. DOI: 10.1016/S1473-3099(15)70060-5. View

11.

Bonelli M, La Monica S, Fumarola C, Alfieri R . Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation. Biochem Pharmacol. 2019; 170:113676. DOI: 10.1016/j.bcp.2019.113676. View

12.

Liu Y, Hu M, Lin P, Li T, Liu S, Wang Y . Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers. Drugs R D. 2022; 22(2):175-182. PMC: 9167418. DOI: 10.1007/s40268-022-00390-7. View

13.

Hamilton E, Infante J . Targeting CDK4/6 in patients with cancer. Cancer Treat Rev. 2016; 45:129-38. DOI: 10.1016/j.ctrv.2016.03.002. View

14.

OLeary B, Finn R, Turner N . Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016; 13(7):417-30. DOI: 10.1038/nrclinonc.2016.26. View

15.

Goel S, Bergholz J, Zhao J . Targeting CDK4 and CDK6 in cancer. Nat Rev Cancer. 2022; 22(6):356-372. PMC: 9149100. DOI: 10.1038/s41568-022-00456-3. View